Rybrevant market set for rapid growth through 2026

The Business Research Company says the global Rybrevant market is expanding on rising non-small cell lung cancer cases, broader genomic testing and wider use of targeted therapies. North America led the market in 2025, while Asia-Pacific is projected to grow fastest over the forecast period.

Why it matters: - Rybrevant is tied to a growing segment of precision oncology, where cancer treatment is increasingly based on molecular markers rather than broad chemotherapy. - The market’s growth reflects rising demand for targeted lung cancer treatments and the broader shift toward biomarker-driven care. - The report highlights how cancer incidence, diagnostic advances and therapy innovation are shaping a fast-moving oncology market.

What happened: - The Business Research Company published its Rybrevant Global Market Report 2026, covering market size, trends and a 2026-2035 forecast. - The report says the Rybrevant market has expanded historically because of higher non-small cell lung cancer incidence, better molecular diagnostics, more approvals for targeted cancer therapies, growth in specialized oncology centers and clinical validation of EGFR-targeted treatments. - The report says future growth will be driven by demand for tailored cancer treatments, wider genomic testing in oncology, higher investment in biologic drug development, more combination therapies and continued innovation in antibody-based therapies. - Rybrevant, or amivantamab, is a monoclonal antibody for non-small cell lung cancer with EGFR exon 20 insertion mutations. - Rybrevant works by targeting the EGFR and MET receptors to slow cancer cell growth and spread while also supporting immune system activation. - The report includes a free sample download and a full report link: the full report.

The details: - The report identifies broader uptake of targeted oncology drugs, expanded use of monoclonal antibodies for lung cancer, stronger precision medicine adoption, more biomarker-driven therapies and new combination cancer regimens as major trends. - Rising cancer patient counts are a key market driver, supported by aging populations and better diagnostic tools that detect cancer earlier and more accurately. - The Canadian Cancer Society reported in May 2024 that 32,100 people were diagnosed with lung cancer in Canada. - The Canadian Cancer Society said lung cancer accounted for 23.5% of all cancer-related deaths in Canada in 2024. - Lung cancer cases among women in Canada rose from 15,800 in 2023 to 17,300 in 2024, according to the Canadian Cancer Society. - In 2025, North America held the largest share of the Rybrevant market because of advanced healthcare infrastructure and early adoption of targeted therapies. - The Asia-Pacific region is expected to post the fastest growth during the forecast period because of rising cancer incidence and expanding healthcare access. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, and the Middle East and Africa. - The 2026 report suite adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and updated technology and future-trend analysis.

Between the lines: - The market story is less about one drug and more about the commercial pull of precision medicine in lung cancer. - Strong regional differences suggest mature markets will be driven by adoption and treatment mix, while emerging markets will be driven by access and diagnosis rates. - The inclusion of expanded analytics tools signals that buyers want more decision support, not just market sizing.

What's next: - The market is likely to keep tracking oncology innovation, especially around combination regimens and antibody-based therapies. - Growth will depend on how quickly genomic testing expands and how widely targeted treatments are adopted across regions. - The report positions Asia-Pacific as the key growth market to watch through the forecast period.

The bottom line: - Rybrevant’s market outlook is being powered by the broader shift toward precision lung cancer care, with North America leading now and Asia-Pacific poised to accelerate next.